Zymeworks Inc.: peers
Zymeworks Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Bellus Health, Cybin D/B/A Helus Pharma, Trillium Therapeutics, Agios Pharmaceuticals, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Zymeworks Inc.base ZYME · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Aurinia Pharmaceuticals Inc. AUPH · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Xenon Pharmaceuticals Inc. XENE · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | AbCellera Biologics Inc. ABCL · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Bellus Health BHN0.F · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Cybin D/B/A Helus Pharma HELP · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Trillium Therapeutics TRIL · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Agios Pharmaceuticals, Inc. AGIO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $2.0 BOct 29, 2026 · Market data5th of 8 | $2.3 BOct 28, 2026 · Market data3rd of 8 | $3.5 BOct 26, 2026 · Market data2nd of 8 | $4.5 BOct 29, 2026 · Market data1st of 8 | $1.9 Blast known, Jul 30, 2023 · Market dataLast known value: no current one6th of 8 | $743 MAug 1, 2026 · Market data8th of 8 | $1.5 Blast known, Jan 1, 2021 · Market dataLast known value: no current one7th of 8 | $2.0 BAug 1, 2026 · Market data4th of 8 | $2.0 B8 ranked |
| Revenue (Better neither way: ranked highest first) | $106 MFY2025 · SEC2nd of 5 | $283 MFY2025 · SEC1st of 5 | $8 MFY2025 · SEC5th of 5 | $75 MFY2025 · SEC3rd of 5 | —— | —— | —— | $54 MFY2025 · SEC4th of 5 | $75 M5 ranked |
| Net income (Higher is better) | $-81 MFY2025 · SEC2nd of 6 | $287 MFY2025 · SEC1st of 6 | $-346 MFY2025 · SEC5th of 6 | $-146 MFY2025 · SEC4th of 6 | —— | $-81 MFY2024 · SEC3rd of 6 | —— | $-413 MFY2025 · SEC6th of 6 | $-114 M6 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | 370December 31, 2025 · Profile2nd of 3 | 174As on 2020 · Profile3rd of 3 | —— | —— | —— | 392As on 2021 · Profile1st of 3 | 3703 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | +10.3%30 days to Oct 29, 2026 · Market data1st of 2 | —— | —— | -1.0%30 days to Oct 29, 2026 · Market data2nd of 2 | —— | —— | —— | —— | +4.6%2 ranked |
| Revenue growth (Higher is better) | +38.9%FY2025 · SEC3rd of 481st81st | +20.4%FY2025 · SEC4th of 470th69th | ———— | +160.6%FY2025 · SEC1st of 495th97th | ———— | ———— | ———— | +48.0%FY2025 · SEC2nd of 483rd91st | +43.5%4 ranked |
| Revenue growth, 3 years a year (Higher is better) | -36.4%FY2025 · SEC3rd of 42nd2nd | +28.3%FY2025 · SEC2nd of 480th87th | ———— | -46.3%FY2025 · SEC4th of 42nd1st | ———— | ———— | ———— | +56.0%FY2025 · SEC1st of 490th96th | -4.1%4 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | 88.5%FY2025 · SEC1st of 290th99th | ———— | ———— | ———— | ———— | ———— | 88.3%FY2025 · SEC2nd of 290th96th | 88.4%2 ranked |
| Operating margin (Higher is better) | -87.3%FY2025 · SEC2nd of 425th9th | 37.1%FY2025 · SEC1st of 497th86th | ———— | -289.0%FY2025 · SEC3rd of 412th3rd | ———— | ———— | ———— | -873.8%FY2025 · SEC4th of 41st0th | -188.2%4 ranked |
| Net margin (Higher is better) | -76.6%FY2025 · SEC2nd of 426th8th | 101.5%FY2025 · SEC1st of 499th100th | ———— | -194.9%FY2025 · SEC3rd of 415th5th | ———— | ———— | ———— | -764.0%FY2025 · SEC4th of 42nd1st | -135.7%4 ranked |
| Free cash flow margin (Higher is better) | -32.6%FY2025 · SEC1st of 332nd15th | ———— | ———— | -231.7%FY2025 · SEC2nd of 314th5th | ———— | ———— | ———— | -698.3%FY2025 · SEC3rd of 33rd1st | -231.7%3 ranked |
| Return on equity (Higher is better) | -26.7%FY2025 · SEC3rd of 656th30th | 59.9%FY2025 · SEC1st of 697th98th | -51.8%FY2025 · SEC6th of 643rd19th | -14.5%FY2025 · SEC2nd of 664th38th | ———— | -42.8%FY2024 · SEC5th of 647th23rd | ———— | -30.2%FY2025 · SEC4th of 654th24th | -28.5%6 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | 7.4×price Oct 28, 2026 · Market dataonly one with it9th19th | ———— | ———— | ———— | ———— | ———— | ———— | 7.4×— |
| Price to sales (Better neither way: ranked highest first) | 18.8×price Oct 29, 2026 · Market data3rd of 482nd93rd | 7.2×price Oct 28, 2026 · Market data4th of 466th83rd | 463.1×price Oct 26, 2026 · Market data1st of 498th100th | 65.7×price Oct 29, 2026 · Market data2nd of 492nd97th | ———— | ———— | ———— | 37.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 42.2×4 ranked |
| Price to book (Better neither way: ranked highest first) | 7.4×price Oct 29, 2026 · Market data1st of 478th90th | 4.0×price Oct 28, 2026 · Market data4th of 460th74th | 6.0×price Oct 26, 2026 · Market data2nd of 472nd85th | 4.6×price Oct 29, 2026 · Market data3rd of 464th79th | ———— | 4.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 1.7׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 5.3×4 ranked |
| Free cash flow yield (Higher is better) | -1.7%price Oct 29, 2026 · Market data1st of 462nd42nd | -1.8%price Oct 28, 2026 · Market data2nd of 462nd41st | -8.1%price Oct 26, 2026 · Market data4th of 446th24th | -3.9%price Oct 29, 2026 · Market data3rd of 456th37th | ———— | -6.9%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | -18.8%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -2.8%4 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 5 of 22FY2025 · Scorecard3rd of 6 | 17 of 21FY2025 · Scorecard1st of 6 | 3 of 14FY2025 · Scorecard4th of 6 | 4 of 20FY2025 · Scorecard5th of 6 | —— | 1 of 5FY2024 · Scorecard5th of 6 | —— | 7 of 14FY2025 · Scorecard2nd of 6 | 22% passed6 ranked |
| Valuation checks (Higher is better) | 0 of 5FY2025 · Scorecard2nd of 4 | 3 of 5FY2025 · Scorecard1st of 4 | 0 of 5FY2025 · Scorecard2nd of 4 | 0 of 5FY2025 · Scorecard2nd of 4 | —— | —— | —— | —— | 0% passed4 ranked |
| Growth checks (Higher is better) | 2 of 6FY2025 · Scorecard3rd of 5 | 6 of 6FY2025 · Scorecard1st of 5 | 0 of 2FY2025 · Scorecard5th of 5 | 1 of 6FY2025 · Scorecard4th of 5 | —— | —— | —— | 3 of 5FY2025 · Scorecard2nd of 5 | 33% passed5 ranked |
| Profitability checks (Higher is better) | 0 of 5FY2025 · Scorecard3rd of 6 | 4 of 5FY2025 · Scorecard1st of 6 | 0 of 3FY2025 · Scorecard3rd of 6 | 0 of 5FY2025 · Scorecard3rd of 6 | —— | 0 of 3FY2024 · Scorecard3rd of 6 | —— | 1 of 5FY2025 · Scorecard2nd of 6 | 0% passed6 ranked |
| Financial health checks (Higher is better) | 2 of 3FY2025 · Scorecard1st of 6 | 2 of 3FY2025 · Scorecard1st of 6 | 2 of 3FY2025 · Scorecard1st of 6 | 2 of 3FY2025 · Scorecard1st of 6 | —— | 1 of 2FY2024 · Scorecard6th of 6 | —— | 2 of 3FY2025 · Scorecard1st of 6 | 67% passed6 ranked |
| Shareholder returns checks (Higher is better) | 1 of 3FY2025 · Scorecard5th of 5 | 2 of 2FY2025 · Scorecard1st of 5 | 1 of 1FY2025 · Scorecard1st of 5 | 1 of 1FY2025 · Scorecard1st of 5 | —— | —— | —— | 1 of 1FY2025 · Scorecard1st of 5 | 100% passed5 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 99.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 6 | 59.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6 | 103.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 6 | 40.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 6 | —— | 31.4%2026-Q2 · 13F6th of 6 | —— | 112.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6 | 79.3%6 ranked |
| Institutions holding (Better neither way: ranked highest first) | 2032026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6 | 2762026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 6 | 2862026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6 | 1642026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 6 | —— | 1002026-Q2 · 13F6th of 6 | —— | 2432026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 6 | 2236 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +2.8 pp2026-Q2 against 2026-Q1 · 13F3rd of 5 | +3.1 pp2026-Q2 against 2026-Q1 · 13F2nd of 5 | +0.6 pp2026-Q2 against 2026-Q1 · 13F4th of 5 | -2.8 pp2026-Q2 against 2026-Q1 · 13F5th of 5 | —— | —— | —— | +4.7 pp2026-Q2 against 2026-Q1 · 13F1st of 5 | +2.8 pp5 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | 2.1%FY2025 · SEC2nd of 249th52nd | 4.3%FY2025 · SEC1st of 272nd72nd | ———— | ———— | ———— | ———— | ———— | ———— | 3.2%2 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Zymeworks Inc.: How market caps are worked out; Aurinia Pharmaceuticals Inc.: How market caps are worked out; Xenon Pharmaceuticals Inc.: How market caps are worked out; AbCellera Biologics Inc.: How market caps are worked out; Bellus Health: How market caps are worked out; Cybin D/B/A Helus Pharma: How market caps are worked out; Trillium Therapeutics: How market caps are worked out; Agios Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Zymeworks Inc. | -87.3%FY2025 | 25th percentile in Healthcaremedian -7.7%, 674 companies | 9th percentile in Canadamedian 8.7%, 114 companies |
| Aurinia Pharmaceuticals Inc. | 37.1%FY2025 | 97th percentile in Healthcaremedian -7.7%, 674 companies | 86th percentile in Canadamedian 8.7%, 114 companies |
| Xenon Pharmaceuticals Inc. | — | — | — |
| AbCellera Biologics Inc. | -289.0%FY2025 | 12th percentile in Healthcaremedian -7.7%, 674 companies | 3rd percentile in Canadamedian 8.7%, 114 companies |
| Bellus Health | — | — | — |
| Cybin D/B/A Helus Pharma | — | — | — |
| Trillium Therapeutics | — | — | — |
| Agios Pharmaceuticals, Inc. | -873.8%FY2025 | 1st percentile in Healthcaremedian -7.7%, 674 companies | 0th percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Zymeworks Inc. | Aurinia Pharmaceuticals Inc. | Xenon Pharmaceuticals Inc. | AbCellera Biologics Inc. | Bellus Health | Cybin D/B/A Helus Pharma | Trillium Therapeutics | Agios Pharmaceuticals, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | $106 MSEC2nd | $283 MSEC1st | $8 MSEC5th | $75 MSEC3rd | — | — | — | $54 MSEC4th |
| 2024 | $76 MSEC2nd | $235 MSEC1st | — | $29 MSEC4th | — | — | — | $37 MSEC3rd |
| 2023 | $76 MSEC2nd | $176 MSEC1st | — | $38 MSEC3rd | — | — | — | $27 MSEC4th |
| 2022 | $412 MSEC2nd | $134 MSEC3rd | $9 MSEC5th | $485 MSEC1st | — | — | — | $14 MSEC4th |
| 2021 | $27 MSEC3rd | $46 MSEC2nd | $18 MSEC4th | $375 MSEC1st | — | — | — | — |
| 2020 | $39 MSEC3rd | $50 MSEC2nd | $32 MSEC4th | $233 MSEC1st | — | $1 MSEC5th | — | — |
| 2019 | — | $0 MSEC4th | $7 MSEC3rd | $12 MSEC2nd | — | — | — | $118 MSEC1st |
| 2018 | — | $0 MSEC2nd | — | — | — | — | — | $94 MSEC1st |
| 2017 | — | $0 MSEC2nd | $0 MSEC3rd | — | — | — | — | $43 MSEC1st |
| 2016 | — | $0 MSEC3rd | $2 MSEC2nd | — | — | — | — | $70 MSEC1st |
| 2015 | — | — | $16 MSEC2nd | — | — | — | — | $59 MSEC1st |
| 2014 | — | — | $28 MSEC2nd | — | — | — | — | $65 MSEC1st |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Zymeworks Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Aurinia Pharmaceuticals Inc.AUPH · 🇨🇦 CanadaSame industry: Biotechnology · Similar size: $2.3 B market cap against $2.0 B · Same country: Canada · Ratios of the last two fiscal years on fileMarket cap $2.3 B (Oct 28, 2026) · revenue $283 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Xenon Pharmaceuticals Inc.XENE · 🇨🇦 CanadaSame industry: Biotechnology · Similar size: $3.5 B market cap against $2.0 B · Same country: Canada · Ratios of the last two fiscal years on fileMarket cap $3.5 B (Oct 26, 2026) · revenue $8 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- AbCellera Biologics Inc.ABCL · 🇨🇦 CanadaSame industry: Biotechnology · Similar size: $4.5 B market cap against $2.0 B · Same country: Canada · Ratios of the last two fiscal years on fileMarket cap $4.5 B (Oct 29, 2026) · revenue $75 M (year to December 2025)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)In the group
- Bellus HealthBHN0.F · 🇨🇦 CanadaSame industry: Biotechnology · Similar size: $1.9 B market cap against $2.0 B · Same country: CanadaMarket cap $1.9 B (last known, Jul 30, 2023)95 of 100 (industry or sector 50 + size 30 + country 15)In the group
- Cybin D/B/A Helus PharmaHELP · 🇨🇦 CanadaSame industry: Biotechnology · Similar size: $743 M market cap against $2.0 B · Same country: Canada · Ratios of the last two fiscal years on fileMarket cap $743 M (Aug 1, 2026)94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)In the group
- Trillium TherapeuticsTRIL · 🇨🇦 CanadaSame industry: Biotechnology · Similar size: $1.5 B market cap against $2.0 B · Same country: CanadaMarket cap $1.5 B (last known, Jan 1, 2021) · revenue $0 M (year to December 2020)93 of 100 (industry or sector 50 + size 28 + country 15)In the group
- Agios Pharmaceuticals, Inc.AGIO · 🇺🇸 USASame industry: Biotechnology · Similar size: $2.0 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on fileMarket cap $2.0 B (Aug 1, 2026) · revenue $54 M (year to December 2025)92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)In the group
- Vir Biotechnology, Inc.VIR · 🇺🇸 USASame industry: Biotechnology · Similar size: $2.0 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on fileMarket cap $2.0 B (Oct 28, 2026) · revenue $69 M (year to December 2025)92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)+ Add
- Generate Biomedicines, Inc.GENB · 🇺🇸 USASame industry: Biotechnology · Similar size: $2.0 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on fileMarket cap $2.0 B (Oct 30, 2026)92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)+ Add
- Zenas BioPharma, Inc.ZBIO · 🇺🇸 USASame industry: Biotechnology · Similar size: $2.0 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on fileMarket cap $2.0 B (Oct 30, 2026) · revenue $10 M (year to December 2025)92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)+ Add
- SELLAS Life Sciences Group, Inc.SLS · 🇺🇸 USASame industry: Biotechnology · Similar size: $2.1 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on fileMarket cap $2.1 B (Oct 30, 2026)92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)+ Add
- Vericel CorporationVCEL · 🇺🇸 USASame industry: Biotechnology · Similar size: $2.1 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on fileMarket cap $2.1 B (Oct 21, 2026) · revenue $276 M (year to December 2025)92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.